Ποια είναι η τιμή για Cytocom, Inc. (CBLI)

Η τιμή για Cytocom, Inc. (CBLI) είναι $3.17

Ποια είναι η κεφαλαιοποίηση αγοράς για Cytocom, Inc. (CBLI)

Η κεφαλαιοποίηση αγοράς για Cytocom, Inc. (CBLI) είναι $34.83M

Cytocom, Inc. (CBLI) Τιμή και Κεφαλαιοποίηση Αγοράς

Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.

Η τιμή για CBLI	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$482,429 $34.83M	NVDA	$5.301T	+15,218,469.34%
$421,725 $34.83M	AAPL	$4.634T	+13,303,540.65%
$377,050 $34.83M	GOOG	$4.143T	+11,894,223.84%
$326,667 $34.83M	MSFT	$3.589T	+10,304,838.43%
$260,009 $34.83M	AMZN	$2.857T	+8,202,079.53%

Η τιμή για CBLI

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$482,429 $34.83M